Milestone Pharmaceuticals (MIST) Projected to Post Earnings on Thursday

Key Points

• Milestone is set to report Q4 2025 results before the market opens on Thursday, March 12, with analysts projecting an EPS loss of ($0.18) and an earnings call scheduled for March 20, 2026 at 12:30 PM ET.
• Company insiders sold a total of 416,327 shares worth about $935,458 in the last quarter (notable individual sales on Dec. 15), leaving insiders with roughly 19.50% ownership.
• Wall Street sentiment is mixed — the consensus rating is a “Hold” with a $8.00 target — while shares trade around $1.65 with a market cap of ~$140.5M and a 52‑week range of $0.63–$3.06.

Milestone Pharmaceuticals (NASDAQ:MIST - Get Free Report) is expected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Parties may review the information on the company's upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 20, 2026 at 12:30 PM ET.

Milestone Pharmaceuticals Stock Performance

Shares of Milestone Pharmaceuticals stock opened at $1.65 on Thursday. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. The company has a fifty day moving average of $1.89 and a 200 day moving average of $2.00. The company has a market capitalization of $140.53 million, a P/E ratio of -2.01 and a beta of 0.48. Milestone Pharmaceuticals has a fifty-two week low of $0.63 and a fifty-two week high of $3.06.

Insider Activity at Milestone Pharmaceuticals

In other Milestone Pharmaceuticals news, insider David Bharucha sold 58,007 shares of the company's stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $2.32, for a total value of $134,576.24. Following the transaction, the insider directly owned 91,993 shares in the company, valued at $213,423.76. This represents a 38.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Lorenz Muller sold 53,566 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $2.32, for a total transaction of $124,273.12. Following the sale, the insider directly owned 196,486 shares of the company's stock, valued at $455,847.52. This represents a 21.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 416,327 shares of company stock valued at $935,458 in the last quarter. Corporate insiders own 19.50% of the company's stock.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its holdings in shares of Milestone Pharmaceuticals by 200,550.0% in the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company's stock valued at $32,000 after buying an additional 16,044 shares in the last quarter. Cetera Investment Advisers acquired a new stake in Milestone Pharmaceuticals in the fourth quarter valued at approximately $42,000. Invesco Ltd. purchased a new position in Milestone Pharmaceuticals in the fourth quarter worth $44,000. Creative Planning increased its position in shares of Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company's stock worth $45,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Raymond James Financial Inc. increased its position in shares of Milestone Pharmaceuticals by 30.1% during the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company's stock worth $84,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors own 86.18% of the company's stock.

Wall Street Analysts Forecast Growth

MIST has been the subject of a number of research reports. TD Cowen raised Milestone Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Monday, December 15th. HC Wainwright reiterated a "buy" rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Wells Fargo & Company raised their target price on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an "overweight" rating in a report on Tuesday, December 16th. Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, January 10th. Finally, Zacks Research lowered shares of Milestone Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 24th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $8.00.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company's research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone's pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone's lead product candidates are delivered through inhalation or systemic administration, reflecting the company's commitment to optimizing therapeutic delivery directly to the lungs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.